Weight loss in Huntington disease increases with higher CAG repeat number
Abstract
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
- Download
- 1.56 MB
REFERENCES
Information & Authors
Information
Published In
Copyright
Publication History
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
- Brain–Periphery Interactions in Huntington’s Disease: Mediators and Lifestyle Interventions, International Journal of Molecular Sciences, 25, 9, (4696), (2024).https://doi.org/10.3390/ijms25094696
- The role of the gut microbiota in neurodegenerative diseases targeting metabolism, Frontiers in Neuroscience, 18, (2024).https://doi.org/10.3389/fnins.2024.1432659
- Clinical Review of Juvenile Huntington’s Disease, Journal of Huntington's Disease, 13, 2, (149-161), (2024).https://doi.org/10.3233/JHD-231523
- Factors Influencing Discharges to Hospice for Patients With Late-Stage Huntington’s Disease, American Journal of Hospice and Palliative Medicine®, (2024).https://doi.org/10.1177/10499091241274725
- Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease, Neurobiology of Disease, 190, (106376), (2024).https://doi.org/10.1016/j.nbd.2023.106376
- Gastrointestinale Störungen bei hyperkinetischen Bewegungsstörungen und AtaxienGastrointestinal disorders in hyperkinetic movement disorders and ataxia, Der Nervenarzt, 95, 8, (697-703), (2024).https://doi.org/10.1007/s00115-024-01655-z
- Emerging Relationship Between the Gut Microbiota and Neurodegenerative Disorders, Altered Metabolism: A Major Contributor of Comorbidities in Neurodegenerative Diseases, (271-301), (2024).https://doi.org/10.1007/978-981-97-4288-2_11
- From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research, International Journal of Molecular Sciences, 24, 16, (13021), (2023).https://doi.org/10.3390/ijms241613021
- Rodent Models of Huntington’s Disease: An Overview, Biomedicines, 11, 12, (3331), (2023).https://doi.org/10.3390/biomedicines11123331
- Effects of mutant huntingtin in oxytocin neurons on non‐motor features of Huntington's disease, Neuropathology and Applied Neurobiology, 49, 2, (2023).https://doi.org/10.1111/nan.12891
- See more
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.
I read the article by Aziz et al. with interest. [1] The authors present a strong case for a hyper-metabolic link between expanding CAG repeat number and the characteristic weight loss in Huntington disease (HD). It is notable that such recognized hyper-metabolic disorders as thyrotoxicosis may also cause chorea. Perhaps therapeutic efforts to lower the metabolic rate by suppressing thyroid function should be investigated in patients with HD.
Reference
1. Aziz NA, van der Burg GB, Landwehrmeyer GB et al. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 2008;71:1506-1513.
Disclosure: The author reports no disclosures.
We appreciate Dr. Gilbert's interest in our findings. [1] The concept of suppressing thyroid function in HD in order to counteract weight loss is intriguing. In addition, as Dr. Gilbert also points out, thyroid hormone excess has been associated with chorea so altering thyroid function might also influence the choreactic movements in HD. [2] However, a number of caveats should be considered.
First, although we found an increased rate of weight loss in HD patients with higher CAG repeat number, the precise mechanisms underlying this association are still unclear. [1] A higher metabolic rate due to mitochondrial dysfunction may be involved, but whether mitochondrial dysfunction in HD would respond to changes in thyroid hormone levels has yet to be investigated. [1]
Second, the hypothalamic-pituitary-thyroid axis function has been rarely studied in HD patients. [3] Although normal basal levels of thyroxine, triiodothyronine and thyroid-stimulating hormone (TSH) have been reported in HD patients, others have found an impaired TSH response to thyrotropin-releasing hormone stimulation. [3] Therefore, more detailed studies of thyroid function in HD are needed.
Third, besides regulating bodies metabolic rate, thyroid hormones have also a myriad of other effects, including the regulation of normal brain function, heart rate and myocardial contractility, gastrointestinal motility and renal water clearance. Moreover, as thyroid hormones affect protein synthesis and degradation, they can also alter the production, responsiveness and metabolic clearance of other hormones. Therefore, iatrogenically induced changes in thyroid function are likely to entail complex alterations in systemic physiology.
However, the concept of direct modulation of the metabolic rate in HD remains intriguing and should be tested in the transgenic disease models now available. It is interesting that caloric restriction, which is known to lower basal metabolic rate, has been shown to slow disease progression, ameliorate weight loss, and increase survival in an HD transgenic mouse model.[4]
References
2. Sudo K, Tashiro K. Hyperthyroidism-associated chorea. Lancet 1998;352:239.
3. Aziz NA, Swaab DF, Pijl H, Roos RA. Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. Rev Neurosci 2007;18:223-251.
4. Duan W, Guo Z, Jiang H, Ware M, Li XJ, Mattson MP. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci USA 2003; 100:2911-2916.
Disclosure: The authors report no disclosures.